REG - Arecor Therapeutics - Arecor AGM statement

Arecor TherapeuticsAnnouncement

23/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220523:nRSW3465Ma&default-theme=true

RNS Number : 3465M  Arecor Therapeutics PLC  23 May 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

 

AGM STATEMENT

 

Building on strong foundations to deliver a transformational year

 

Cambridge, UK, 23 May 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
provides the following update ahead of its Annual General Meeting, held today
at 1.00 pm at the offices of Covington & Burling LLP, 22 Bishopsgate,
London EC2N 4BQ.

 

At the meeting, Andrew Richards, Non-Executive Chair, will make the following
statement:

 

"2021 was a truly transformational year for Arecor and the Company has
continued to make huge strides to continue this trajectory of growth.  During
the year, our pipeline of proprietary and partnered products received
validation through both exceptional clinical data and partnership progress. It
is our vision to create a sustainable biopharmaceutical company, by
rejuvenating existing therapeutic products to make them better, safer and more
convenient to use.

 

Our two lead clinical stage programmes are focused on improving the lives of
those living with diabetes.  The impact that the growing global number of
diabetes patients is having on our resources, health sector and lives cannot
be underestimated.  The Phase I clinical trial data for both our lead
product, AT247, an ultra-rapid insulin and for our second product AT278, a
concentrated rapid insulin targeting patients who require higher volumes of
insulin, excelled our expectations.  We believe that our products will
provide that key to unlock the future treatment landscape for diabetes.

 

With our partnered portfolio continuing to attractive high calibre
pharmaceutical companies and strong support from our shareholders following
our successful IPO on the London Stock Exchange last year, we believe that
Arecor is well positioned to both deliver on existing programmes and attract
new and exciting opportunities in the coming year to create long-term
shareholder value."

 

Further information about the AGM can be found in the investor centre section
of our website https://arecor.com/investor-centre/shareholder-information/
(https://arecor.com/investor-centre/shareholder-information/) . To register
for the webinar, click here
(https://us06web.zoom.us/webinar/register/WN_kgVOcX_eTDeLnx7viYTswA) .

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMATMRTMTTTBLT